Literature DB >> 15500430

Is it time for medical therapy for aortic valve disease?

Nalini M Rajamannan1.   

Abstract

Calcific aortic stenosis is the most common indication for surgical valve replacement. Currently there are no medical therapies approved for the treatment of this disease. This review will summarize the clinical and experimental studies published over the past 5 years that indicate that medical therapy may be an option for this patient population.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15500430      PMCID： PMC3951874          DOI： 10.1586/14779072.2.6.845

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN： 1477-9072


  35 in total

Review 1.  Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts.

Authors:  Nalini M Rajamannan; Bernard Gersh; Robert O Bonow
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

2.  Hypercholesterolemic aortic-valve disease.

Authors:  Nalini M Rajamannan; William D Edwards; Thomas C Spelsberg
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

3.  The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening.

Authors:  John E Cosmi; Smadar Kort; Paul A Tunick; Barry P Rosenzweig; Robin S Freedberg; Edward S Katz; Robert M Applebaum; Itzhak Kronzon
Journal:  Arch Intern Med       Date:  2002-11-11

4.  Experimental aortic valve stenosis in rabbits.

Authors:  Marie-Claude Drolet; Marie Arsenault; Jacques Couet
Journal:  J Am Coll Cardiol       Date:  2003-04-02       Impact factor: 24.094

5.  Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Margaret Springett; Thomas C Sebo; Marek Niekrasz; Joseph P McConnell; Ravinder J Singh; Neil J Stone; Robert O Bonow; Thomas C Spelsberg
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

6.  Human aortic valve calcification is associated with an osteoblast phenotype.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

7.  Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).

Authors:  Anand Chockalingam; S Venkatesan; T Subramaniam; V Jagannathan; S Elangovan; R Alagesan; G Gnanavelu; Smrita Dorairajan; B P Krishna; V Chockalingam
Journal:  Am Heart J       Date:  2004-04       Impact factor: 4.749

8.  Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis.

Authors:  Umesh N Khot; Gian M Novaro; Zoran B Popović; Roger M Mills; James D Thomas; E Murat Tuzcu; Donald Hammer; Steven E Nissen; Gary S Francis
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

Review 9.  Is aortic stenosis a preventable disease?

Authors:  Kwan-Leung Chan
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

10.  Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community.

Authors:  Michael F Bellamy; Patricia A Pellikka; Kyle W Klarich; A Jamil Tajik; Maurice Enriquez-Sarano
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094
View more
  1 in total

1.  Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.

Authors:  Cordelia J Barrick; Reade B Roberts; Mauricio Rojas; Nalini M Rajamannan; Carolyn B Suitt; Kevin D O'Brien; Susan S Smyth; David W Threadgill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.